NeoGenomics price target lowered to $20 from $21 at TD Cowen

TD Cowen lowered the firm’s price target on NeoGenomics to $20 from $21 and keeps a Buy rating on the shares. The firm said its recent price decline creates a good entry point and mangement comments that they are starting to evaluate M&A opportunities could be a culprit for the sell-off; though we believe CEO Smith is savvy and sees potential to add value with accretive tuck in that won’t disrupt the story.